Changjiang Pharmaceutical Group Crecimiento futuro
Future controles de criterios 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Changjiang Pharmaceutical Group.
Información clave
n/a
Tasa de crecimiento de los beneficios
n/a
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Auto Components | 24.6% |
| Tasa de crecimiento de los ingresos | n/a |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | None |
| Última actualización | n/a |
Actualizaciones recientes sobre el crecimiento futuro
No hay actualizaciones
Recent updates
Revenues Not Telling The Story For Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) After Shares Rise 45%
Sep 30
Investors Don't See Light At End Of Changjiang Pharmaceutical Group Co., Ltd.'s (SZSE:300391) Tunnel And Push Stock Down 31%
Aug 11Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough
Jun 17Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) Looks Inexpensive After Falling 38% But Perhaps Not Attractive Enough
Apr 17Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) Not Doing Enough For Some Investors As Its Shares Slump 25%
Feb 27En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Changjiang Pharmaceutical Group no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.
Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.
Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 9/30/2024 | 277 | -671 | -220 | -212 | N/A |
| 6/30/2024 | 795 | -734 | -197 | -190 | N/A |
| 3/31/2024 | 1,120 | -630 | -213 | -205 | N/A |
| 12/31/2023 | 1,198 | -606 | -154 | -147 | N/A |
| 9/30/2023 | 1,215 | -167 | 82 | 62 | N/A |
| 6/30/2023 | 1,099 | -7 | 57 | 35 | N/A |
| 3/31/2023 | 1,207 | -61 | 6 | 0 | N/A |
| 1/1/2023 | 1,615 | -23 | -118 | -66 | N/A |
| 9/30/2022 | 1,966 | -20 | -222 | -50 | N/A |
| 6/30/2022 | 2,056 | -75 | -101 | 103 | N/A |
| 3/31/2022 | 2,122 | 4 | 25 | 225 | N/A |
| 1/1/2022 | 2,362 | 49 | 89 | 231 | N/A |
| 9/30/2021 | 2,388 | 121 | 168 | 233 | N/A |
| 6/30/2021 | 2,143 | 117 | 73 | 106 | N/A |
| 3/31/2021 | 1,874 | 90 | -16 | 3 | N/A |
| 12/31/2020 | 1,215 | 25 | 14 | 33 | N/A |
| 9/30/2020 | 784 | -696 | -58 | -56 | N/A |
| 6/30/2020 | 636 | -723 | -35 | -34 | N/A |
| 3/31/2020 | 591 | -700 | 15 | 20 | N/A |
| 12/31/2019 | 725 | -670 | 17 | 22 | N/A |
| 9/30/2019 | 763 | 22 | 86 | 96 | N/A |
| 6/30/2019 | 897 | 81 | 97 | 108 | N/A |
| 3/31/2019 | 988 | 115 | 176 | 185 | N/A |
| 12/31/2018 | 881 | 102 | 128 | 137 | N/A |
| 9/30/2018 | 947 | 123 | 125 | 130 | N/A |
| 6/30/2018 | 898 | 103 | N/A | 76 | N/A |
| 3/31/2018 | 829 | 80 | N/A | -18 | N/A |
| 12/31/2017 | 744 | 70 | N/A | 39 | N/A |
| 9/30/2017 | 564 | 53 | N/A | 9 | N/A |
| 6/30/2017 | 409 | 35 | N/A | 25 | N/A |
| 3/31/2017 | 241 | 5 | N/A | -7 | N/A |
| 12/31/2016 | 235 | 4 | N/A | -18 | N/A |
| 9/30/2016 | 214 | 6 | N/A | 24 | N/A |
| 6/30/2016 | 194 | -1 | N/A | 20 | N/A |
| 3/31/2016 | 195 | 4 | N/A | 58 | N/A |
| 12/31/2015 | 191 | 5 | N/A | 41 | N/A |
| 9/30/2015 | 214 | 11 | N/A | -3 | N/A |
| 6/30/2015 | 231 | 21 | N/A | -51 | N/A |
| 3/31/2015 | 244 | 26 | N/A | -37 | N/A |
| 12/31/2014 | 243 | 29 | N/A | -39 | N/A |
| 9/30/2014 | 254 | 35 | N/A | 18 | N/A |
| 6/30/2014 | 248 | 34 | N/A | 23 | N/A |
| 3/31/2014 | 254 | 34 | N/A | -10 | N/A |
| 12/31/2013 | 255 | 35 | N/A | 22 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Insufficient data to determine if 300391's forecast earnings growth is above the savings rate (2.9%).
Beneficios vs. Mercado: Insufficient data to determine if 300391's earnings are forecast to grow faster than the CN market
Beneficios de alto crecimiento: Insufficient data to determine if 300391's earnings are expected to grow significantly over the next 3 years.
Ingresos vs. Mercado: Insufficient data to determine if 300391's revenue is forecast to grow faster than the CN market.
Ingresos de alto crecimiento: Insufficient data to determine if 300391's revenue is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if 300391's Return on Equity is forecast to be high in 3 years time